Evaluation of Aerosol Drug Delivery with Concurrent Low- and High-flow Nasal Oxygen

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2022 Oct 13

PMID 36225335

Authors

Barry Murphy

Marc Mac Giolla Eain

Mary Joyce

James B Fink

Ronan MacLoughlin

Affiliations

Soon will be listed here.

Abstract

Question Addressed By Study: Administration of aerosol to patients receiving high-flow nasal oxygen (HFNO) ranges from concurrent aerosol delivery by mouthpiece to aerosol cannula alone. This study examines the conditions to provide optimal aerosol delivery with low- or high-flow nasal oxygen with concurrent mouthpiece or through nasal cannula alone, and the impact on fugitive aerosols.

Materials And Methods: A vibrating mesh nebuliser delivered salbutamol mouthpiece, aerosol holding chamber and nasal cannula to an adult head model simulating relaxed breathing. The mean±sd inhaled dose (%) was assayed from a filter distal to the trachea. Optical particle sizers were used to measure fugitive aerosol concentrations during aerosol delivery.

Results: Concurrent low-flow nasal oxygen (LFNO) and aerosol delivery with a mouthpiece and aerosol holding chamber increased the inhaled dose (%) available, 31.44±1.33% when supplemented with 2 L·min of nasal oxygen. Concurrent HFNO above 30 L·min resulted in a lower inhaled dose (%) compared to aerosol delivered through HFNO alone. The addition of concurrent LFNO or HFNO resulted in no increase in aerosol levels in the test room.

Answer To Question Posed: Concurrent LFNO with a mouthpiece and aerosol holding chamber is an effective and safe means of aerosol delivery.

Citing Articles

Performance Characterisation of the Airvo2 Nebuliser Adapter in Combination with the Aerogen Solo Vibrating Mesh Nebuliser for in Line Aerosol Therapy during High Flow Nasal Oxygen Therapy.

MacLoughlin R, Mac Giolla Eain M Pharmaceutics. 2024; 16(4).

PMID: 38675226 PMC: 11053618. DOI: 10.3390/pharmaceutics16040565.

In-Line Aerosol Therapy via Nasal Cannula during Adult and Paediatric Normal, Obstructive, and Restrictive Breathing.

Mac Giolla Eain M, MacLoughlin R Pharmaceutics. 2023; 15(12).

PMID: 38140020 PMC: 10747070. DOI: 10.3390/pharmaceutics15122679.

Exhaled patient derived aerosol dispersion during awake tracheal intubation with concurrent high flow nasal therapy.

Mac Giolla Eain M, Nolan K, Murphy B, McCaul C, MacLoughlin R J Clin Monit Comput. 2023; 37(5):1265-1273.

PMID: 36930390 PMC: 10022553. DOI: 10.1007/s10877-023-00990-x.

References

Li J, Tu M, Yang L, Jing G, Fink J, Burtin C . Worldwide Clinical Practice of High-Flow Nasal Cannula and Concomitant Aerosol Therapy in the Adult ICU Setting. Respir Care. 2021; 66(9):1416-1424. DOI: 10.4187/respcare.08996. View

Li J, Gong L, Fink J . The Ratio of Nasal Cannula Gas Flow to Patient Inspiratory Flow on Trans-nasal Pulmonary Aerosol Delivery for Adults: An in Vitro Study. Pharmaceutics. 2019; 11(5). PMC: 6571744. DOI: 10.3390/pharmaceutics11050225. View

Joyce M, McGrath J, Mac Giolla Eain M, OSullivan A, Byrne M, MacLoughlin R . Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation. Pharmaceutics. 2021; 13(2). PMC: 7912998. DOI: 10.3390/pharmaceutics13020199. View

Singh V, Gupta P, Khatana S, Bhagol A . Supplemental oxygen therapy: Important considerations in oral and maxillofacial surgery. Natl J Maxillofac Surg. 2012; 2(1):10-4. PMC: 3304228. DOI: 10.4103/0975-5950.85846. View

Ari A, Dornelas de Andrade A, Sheard M, Alhamad B, Fink J . Performance Comparisons of Jet and Mesh Nebulizers Using Different Interfaces in Simulated Spontaneously Breathing Adults and Children. J Aerosol Med Pulm Drug Deliv. 2014; 28(4):281-9. DOI: 10.1089/jamp.2014.1149. View

Frank E, Ishau S, Maier A, Reutman S, Reichard J . An occupational exposure limit (OEL) approach to protect home healthcare workers exposed to common nebulized drugs. Regul Toxicol Pharmacol. 2019; 106:251-261. DOI: 10.1016/j.yrtph.2019.04.021. View

Rochwerg B, Einav S, Chaudhuri D, Mancebo J, Mauri T, Helviz Y . The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Med. 2020; 46(12):2226-2237. PMC: 7670292. DOI: 10.1007/s00134-020-06312-y. View

Hess D . Aerosol Therapy During Noninvasive Ventilation or High-Flow Nasal Cannula. Respir Care. 2015; 60(6):880-91. DOI: 10.4187/respcare.04042. View

Mirabelli M, Zock J, Plana E, Anto J, Benke G, Blanc P . Occupational risk factors for asthma among nurses and related healthcare professionals in an international study. Occup Environ Med. 2007; 64(7):474-9. PMC: 2078479. DOI: 10.1136/oem.2006.031203. View

10.

Bhashyam A, Wolf M, Marcinkowski A, Saville A, Thomas K, Carcillo J . Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv. 2008; 21(2):181-8. DOI: 10.1089/jamp.2007.0662. View

11.

Reminiac F, Vecellio L, Heuze-Vourch N, Petitcollin A, Respaud R, Cabrera M . Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy. J Aerosol Med Pulm Drug Deliv. 2015; 29(2):134-41. DOI: 10.1089/jamp.2015.1219. View

12.

Long C, Suh H, Catalano P, Koutrakis P . Using time- and size-resolved particulate data to quantify indoor penetration and deposition behavior. Environ Sci Technol. 2001; 35(10):2089-99. DOI: 10.1021/es001477d. View

13.

Hibbitts A, OMahony A, Forde E, Nolan L, Ogier J, Desgranges S . Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells. J Aerosol Med Pulm Drug Deliv. 2014; 27(6):466-77. DOI: 10.1089/jamp.2013.1045. View

14.

Mac Giolla Eain M, Cahill R, MacLoughlin R, Nolan K . Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control. Drug Deliv. 2021; 29(1):10-17. PMC: 8725970. DOI: 10.1080/10717544.2021.2015482. View

15.

Beach J, Campbell M, Andrews D . Exposure of health care workers to pentamidine isethionate. Occup Med (Lond). 1999; 49(4):243-5. DOI: 10.1093/occmed/49.4.243. View

16.

White G, Mazurek J, Moorman J . Asthma in health care workers: 2008 and 2010 Behavioral Risk Factor Surveillance System Asthma Call-back Survey. J Occup Environ Med. 2013; 55(12):1463-8. PMC: 4524494. DOI: 10.1097/JOM.0000000000000006. View

17.

Perry S, Kesser K, Geller D, Selhorst D, Rendle J, Hertzog J . Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med. 2013; 14(5):e250-6. DOI: 10.1097/PCC.0b013e31828a7f79. View

18.

Bennett G, Joyce M, Sweeney L, MacLoughlin R . In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal Therapy. Pulm Ther. 2020; 5(1):43-54. PMC: 6967176. DOI: 10.1007/s41030-019-0086-x. View

19.

McGrath J, OSullivan A, Bennett G, OToole C, Joyce M, Byrne M . Investigation of the Quantity of Exhaled Aerosols Released into the Environment during Nebulisation. Pharmaceutics. 2019; 11(2). PMC: 6409895. DOI: 10.3390/pharmaceutics11020075. View

20.

McGrath J, OToole C, Bennett G, Joyce M, Byrne M, MacLoughlin R . Investigation of Fugitive Aerosols Released into the Environment during High-Flow Therapy. Pharmaceutics. 2019; 11(6). PMC: 6630289. DOI: 10.3390/pharmaceutics11060254. View